FDA Clears Alvotech's Second Reykjavik Suite for SIMLANDI US Supply

Alvotech (NASDAQ: ALVO; ALVO-SDB) announced on October 5, 2026 that the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02 (adalimumab-ryvk), the biosimilar to Humira marketed in the U.S. as SIMLANDI. The approval allows drug substance for U.S. commercial supply to be manufactured in a second production suite, DSM2, at the company's Reykjavik facility, doubling the drug substance manufacturing capacity available to support U.S. supply of the product.

Context — why a second manufacturing suite matters for Alvotech

Alvotech is a Reykjavik-based biotechnology company founded by Robert Wessman that develops and manufactures biosimilar medicines, with five biosimilars already approved and marketed across multiple global markets. The U.S. commercialisation of SIMLANDI runs through Teva Pharmaceuticals, which holds exclusive rights to commercialise the product in the United States, while Alvotech retains responsibility for development and manufacturing. That division of labour makes Alvotech's manufacturing footprint the binding constraint on how much product Teva can sell into the U.S. market.

Until this approval, AVT02 drug substance for U.S. commercial supply could only be produced in DSM1. DSM2 was already approved for commercial drug substance manufacturing for European markets, covering AVT02, AVT03 and AVT05, but that European clearance did not extend to U.S. supply. The FDA supplement closes that gap, giving Alvotech a second qualified suite for the U.S. market rather than a single point of production.

The company said the approval also confirms resolution of inspection-related matters at the Reykjavik site. The FDA closed its most recent inspection of the facility in July 2026 with a Voluntary Action Indicated classification, the least severe of the agency's inspection outcomes. Alvotech said it therefore expects the FDA to be able to act on other pending applications tied to the facility according to their respective goal dates.

Lisa Graver, Alvotech's Chief Executive Officer, said the approval is important both operationally and as a further regulatory milestone for the Reykjavik facility. She said the addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market, and that it reflects progress the company's teams have made in strengthening quality systems and manufacturing operations at the site.

Data — what the FDA approval changes

The operational change is binary: before the supplement, U.S. commercial drug substance for AVT02 came from one suite, DSM1. After it, Alvotech can manufacture that material in either DSM1 or DSM2. The company describes DSM2 as supporting the complete drug substance manufacturing process, including cell culture and purification, so the second suite is not a partial or finishing-only line.

The commercial footprint of AVT02 gives the capacity question its weight. The product is a monoclonal antibody approved as a biosimilar to Humira in more than 50 countries, including the United States, Europe, Canada and Australia. It is marketed in the U.S. as SIMLANDI and under private label, in Europe as HUKYNDRA, in Canada as SIMLANDI and in Australia as ADALACIP.

Alvotech did not disclose the financial terms of the approval, the volume uplift it expects, or the capital cost of qualifying DSM2 for U.S. supply. The report also does not give revenue figures for SIMLANDI or a timeline for any capacity ramp.

The pending pipeline now sits closer to the front of the queue. Alvotech named four application groups it expects the FDA to be able to act on according to their goal dates: AVT05, a proposed biosimilar to Simponi and Simponi Aria (golimumab); AVT06, a proposed biosimilar to Eylea (aflibercept); AVT03, a proposed biosimilar to Prolia and Xgeva (denosumab); and AVT16/AVT80, proposed biosimilars to Entyvio (vedolizumab). Each remains subject to the FDA's individual review and regulatory decision.

Analysis — who is exposed and what the approval does not fix

For Alvotech, the second suite converts a single-site dependency into redundancy. A manufacturing interruption at DSM1 would previously have threatened U.S. commercial supply of AVT02 directly; with two qualified suites, the company has an internal alternative. That matters more for a biosimilar than for a small-molecule generic, because biologic drug substance production cannot be quickly replicated at a third-party site without fresh regulatory filings.

The read-across runs to Teva Pharmaceuticals, Alvotech's U.S. commercialisation partner for SIMLANDI. Teva's ability to compete in the U.S. adalimumab biosimilar market depends on Alvotech's supply reliability rather than on Teva's own manufacturing. Capacity redundancy at the Reykjavik site reduces the risk of supply gaps that would undercut Teva's commercial position.

The July 2026 VAI classification is the more consequential signal for the pipeline. A VAI outcome, rather than an Official Action Indicated, is what allows the FDA to proceed with pending applications that reference the facility. Alvotech's own framing is that the FDA should now be able to take action on AVT05, AVT06, AVT03 and AVT16/AVT80 according to their goal dates. Those four programmes span immunology, ophthalmology and bone health, and each approval decision is a separate binary event.

The counter-argument is that inspection resolution removes a procedural obstacle without guaranteeing an approval. The report states each application remains subject to the FDA's individual review and regulatory decision, and the company gave no dates. Alvotech's pipeline commentary is a forward-looking expectation, not a cleared outcome.

Positioning follows that asymmetry. Holders of ALVO are effectively long a sequence of FDA decisions on four biosimilar candidates plus the U.S. commercial trajectory of SIMLANDI, while the manufacturing risk that previously sat alongside those catalysts has narrowed. The company did not disclose how much of its U.S. supply obligation it expects DSM2 to carry.

Outlook — what to watch next

The immediate items are the pending BLA decisions Alvotech flagged: AVT05 for golimumab, AVT06 for aflibercept, AVT03 for denosumab, and AVT16/AVT80 for vedolizumab. The company did not give target action dates, so the goal dates themselves are the calendar to track. Any FDA action on those applications would be the first test of whether the VAI closure translates into approvals.

On the commercial side, the metric to watch is whether SIMLANDI's U.S. supply expands now that two suites are qualified. Alvotech did not publish a volume target or a capacity figure, so there is no stated level to measure against; the company's own statement that DSM2 doubles capacity available for U.S. supply is the only quantitative anchor it provided.

Further FDA inspections of the Reykjavik facility are the structural risk to monitor, since the site's status underpins both the approved product and the pending pipeline. Alvotech gave no schedule for future inspections.

Frequently Asked Questions

What does the FDA approval mean for Alvotech shareholders?

It removes a manufacturing constraint rather than adding revenue directly. AVT02 drug substance for U.S. commercial supply can now come from either DSM1 or DSM2, so a single-suite failure no longer threatens U.S. supply of SIMLANDI. The company did not disclose any financial terms, volume targets or capacity figures tied to the approval, so the earnings impact is not quantified in the report.

What happens next for Alvotech's pipeline after the Reykjavik inspection closure?

The FDA closed its most recent inspection of the Reykjavik site in July 2026 with a Voluntary Action Indicated classification. Alvotech said it expects the FDA to be able to act on pending applications tied to the facility according to their goal dates. Those are AVT05, AVT06, AVT03 and AVT16/AVT80. Each remains subject to the FDA's own review and decision.

Why does a second manufacturing suite matter for a biosimilar?

Biological drug substance production cannot be moved to a new site quickly without regulatory clearance. DSM2 was already approved for European commercial supply, including AVT02, AVT03 and AVT05, but that did not cover the U.S. market. The FDA supplement extends U.S. clearance to the second suite, which supports the full process including cell culture and purification.

Bottom Line

The approval doubles Alvotech's qualified U.S. drug substance capacity for SIMLANDI and clears the inspection overhang that had gated four pending biosimilar applications.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.